- $2.41bn
- $2.82bn
- $2.60bn
- 68
- 70
- 25
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.03 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 12.42 | ||
| Price to Sales | 0.92 | ||
| EV to EBITDA | 31.87 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.26% | ||
| Return on Equity | -9.51% | ||
| Operating Margin | -9.55% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 553.31 | 1,093.96 | 2,032.71 | 2,406.84 | 2,602.41 | 2,665.26 | 2,760.74 | 44.16% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Teladoc Health, Inc. provides virtual healthcare services. The Company operates through two segments: Teladoc Health Integrated Care (Integrated Care) and BetterHelp. The Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed primarily on a business-to-business (B2B) basis. The BetterHelp segment primarily consists of its direct-to-consumer (D2C) mental health platform. The online counseling and therapy services are provided via its network of over 40,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs.
Directors
- David Snow CHM (66)
- Jason Gorevic CEO (49)
- Mala Murthy CFO (57)
- Arnnon Geshuri CHO (51)
- Richard Napolitano SVP (54)
- Daniel Trencher SVP (49)
- Andrew Turitz SVP (48)
- Stephanie Verstraete CMO (52)
- Yulun Wang OTH (60)
- Adam Vandervoort SEC (46)
- Christopher Bischoff IND (47)
- Karen Daniel IND (63)
- Sandra Fenwick IND (70)
- William Frist IND (69)
- Catherine Jacobson IND (57)
- Thomas McKinley IND (69)
- Kenneth Paulus IND (61)
- David Shedlarz IND (72)
- Mark Smith IND (69)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 16th, 2008
- Public Since
- July 1st, 2015
- No. of Shareholders
- 91
- No. of Employees
- 5,600
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 169,314,029
- Address
- 2 Manhattanville Rd Ste 203, PURCHASE, 10577-2118
- Web
- https://www.teladochealth.com/
- Phone
- +1 2036352002
- Contact
- Patrick Feeley
- Auditors
- Ernst & Young LLP
Latest News for TDOC
Upcoming Events for TDOC
Q1 2024 Teladoc Health Inc Earnings Release
Q1 2024 Teladoc Health Inc Earnings Call
Teladoc Health Inc Annual Shareholders Meeting
Teladoc Health Inc Annual Shareholders Meeting
Q2 2024 Teladoc Health Inc Earnings Release
Similar to TDOC
Agilon Health
New York Stock Exchange
AMERICAN WELL
New York Stock Exchange
AMN Healthcare Services
New York Stock Exchange
Ati Physical Therapy
New York Stock Exchange
Auna SAA
New York Stock Exchange
FAQ
As of Today at 19:21 UTC, shares in Teladoc Health are trading at $14.21. This share price information is delayed by 15 minutes.
Shares in Teladoc Health last closed at $14.21 and the price had moved by -45.6% over the past 365 days. In terms of relative price strength the Teladoc Health share price has underperformed the S&P500 Index by -56.06% over the past year.
The overall consensus recommendation for Teladoc Health is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Teladoc Health does not currently pay a dividend.
Teladoc Health does not currently pay a dividend.
Teladoc Health does not currently pay a dividend.
To buy shares in Teladoc Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $14.21, shares in Teladoc Health had a market capitalisation of $2.41bn.
Here are the trading details for Teladoc Health:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: TDOC
Based on an overall assessment of its quality, value and momentum Teladoc Health is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Teladoc Health is $19.84. That is 39.62% above the last closing price of $14.21.
Analysts covering Teladoc Health currently have a consensus Earnings Per Share (EPS) forecast of -$1.04 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Teladoc Health. Over the past six months, its share price has underperformed the S&P500 Index by -34.47%.
As of the last closing price of $14.21, shares in Teladoc Health were trading -28.25% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Teladoc Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $14.21.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Teladoc Health's management team is headed by:
- David Snow - CHM
- Jason Gorevic - CEO
- Mala Murthy - CFO
- Arnnon Geshuri - CHO
- Richard Napolitano - SVP
- Daniel Trencher - SVP
- Andrew Turitz - SVP
- Stephanie Verstraete - CMO
- Yulun Wang - OTH
- Adam Vandervoort - SEC
- Christopher Bischoff - IND
- Karen Daniel - IND
- Sandra Fenwick - IND
- William Frist - IND
- Catherine Jacobson - IND
- Thomas McKinley - IND
- Kenneth Paulus - IND
- David Shedlarz - IND
- Mark Smith - IND